Russian University successfully finishes trials of world's first COVID-19 vaccine

Share

Bharat Biotech's vaccine candidate reportedly developed an "effective" immune response during the pre-clinical phase of its trials between late-June and early-July.

Including Moderna's vaccine candidate, just four potential vaccines have advanced to phase 3 trials so far.

Moderna Inc's experimental vaccine for Covid-19 showed it was safe and provoked immune responses in all 45 healthy volunteers in an ongoing early-stage study, USA researchers reported on Tuesday.

Tarasov said,"Sechenov University has successfully completed tests on volunteers of the world's first vaccine against coronavirus". They will be tracked for two years to see whether they get COVID-19 or have any adverse reactions to the vaccine.

Meanwhile, many countries launched massive efforts to develop a vaccine.

A vaccine candidate has to undergo three different phases before it can be granted approval by a health regulatory authority such as the US' Food and Drug Administration.

The first stage of testing at the university commenced on 18 June in a group of 18 participants.

Russian has announced it has completed the human trials of a new Coronavirus vaccine, adding that test patients used for the trials will be discharged soon and the vaccine could be available by August.

Prosecutors seek Friday court appearance for Epstein friend
Ghislaine Maxwell is accused of procuring underaged girls for the U.S. billionaire, who killed himself while in jail. He denies all the allegations against her and says he does not remember meeting her.

India's COVID-19 tally is close to hitting the one million mark, with new cases pushing the total number to 93,6181 on Wednesday.

More than half of the participants had side effects, including fatigue, chills, headaches, muscle aches and pain at the injection site.

The Oxford AstraZeneca COVID-29 vaccine is now under phase three in the Uk, Brazil and South Africa and is expected to be rolled out soon.

"These Phase 1 data demonstrate that vaccination with mRNA-1273 elicits a robust immune response across all dose levels and clearly support the choice of 100 µg in a prime and boost regimen as the optimal dose for the Phase 3 study", said Tal Zaks, the chief medical officer of Moderna.

Director-General of the Indian Council of Medical Research (ICMR) Balaram Bhargava stressed in a press briefing on Tuesday that India has prioritised its vaccine development efforts, as more than half a million people have succumbed to COVID-19 around the world.

The focus will also be on ramping up the vaccine's production.

The main researcher of this Russian university claims all human trials of the vaccine have been completed, but, only 40 volunteers were involved in the study.

In the Phase 1 trial, led by Lisa A Jackson of Kaiser Permanente Washington Health Research Institute in Seattle, the 45 participants ages 18 to 55 years received the candidate vaccine.

Share